β-tubulin-Ⅲ基因表达与Ⅱ期非小细胞肺癌患者化疗敏感度的关系

江洪; 周星明; 王小红; 苏丹; 陶开义

doi:10.3971/j.issn.1000-8578.2013.06.015

β-tubulin-Ⅲ基因表达与Ⅱ期非小细胞肺癌患者化疗敏感度的关系

Relationship between Expression Level of β-tubulin-Ⅲ and Sensitivity of Chemotherapy in Patients with Stage Ⅱ Non-small Cell Lung Cancer

摘要

摘要: 目的探讨Ⅱ期非小细胞肺癌(NSCLC)中Ⅲ型β微管蛋白（β-tubulin-Ⅲ）mRNA表达与诺维本+顺铂（NP）方案化疗敏感度的关系。方法单基因定量法检测已手术Ⅱ期NSCLC患者肿瘤组织中β-tubulin-ⅢmRNA表达，所有患者行NP方案化疗，并随访患者的无瘤生存时间（DFS）和总体生存率（OS），统计学分析β-tubulin-ⅢmRNA表达水平与患者DFS和OS的关系。结果 73例患者的OS与β-tubulin-Ⅲ的表达有关(P<0.01)，患者的DFS与β-tubulin-Ⅲ的表达及淋巴结转移情况有关(P<0.01)。β-tubulin-Ⅲ低表达者的OS、DFS均高于β-tubulin-Ⅲ高表达者(P<0.05)。结论 Ⅱ期NSCLC患者肿瘤组织中β-tubulin-Ⅲ表达水平可能是预测患者预后及化疗敏感度的一个指标，为选择合适化疗药物提供参考。

Abstract: Objective To explore the relationship between chemotherapy sensitivity and the expression level of β- tubulin-Ⅲ mRNA in patients with stage Ⅱ NSCLC. Methods The expression of β-tubulin-Ⅲ mRNA was measured by Quanti-Gene assay.All patients accepted NP chemotherapy, and disease-free survival time (DFS) and overall survival time (OS) was analyzed. Results The OS of patients was related with the expression level of β-tubulin-Ⅲ (P<0.01), the DFS was related with the expression level of β-tubulin-Ⅲ and lymph node metastasis (P<0.01).The OS and DFS in patients with lower-expression level of β- tubulin-Ⅲ were longer than those with over-expression (P<0.05). Conclusion The expression of β-tubulin-Ⅲ in patients with stage Ⅱ NSCLC might be a predictive factor for chemotherapy sensitivity and the prognosis,and a reference for agents choose.

HTML全文

参考文献(11)

施引文献

资源附件(0)